Phase 2, double-blind, placebo-controlled study to evaluate the effectiveness of two doses of AP-472 as adjunctive therapy to levodopa in Parkinson's disease (PD) participants with motor fluctuations
NCT ID NCT07432958
Summary
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 12 weeks. Participants will be randomly assigned to receive one of the two doses of AP-472 or a placebo. Neither the participants nor the study staff will know which treatment is given. The study includes a screening period, a 4-week period during which Parkinson's medications must remain stable, and an 8-week treatment period. During the treatment period, limited adjustments to levodopa are allowed if needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Augusta University Medical Center
Augusta, Georgia, 30912-0020, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215-5400, United States
-
Central Texas Neurology Consultants
Round Rock, Texas, 78681-3578, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195-0001, United States
-
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
Los Alamitos, California, 90720-3108, United States
-
Duke Neurological Disorders Clinic
Durham, North Carolina, 27705, United States
-
EvergreenHealth
Kirkland, Washington, 98034-3013, United States
-
Joan and Sanford I. Weill Department of Medicine
New York, New York, 10065, United States
-
Keck Medicine of USC - USC Healthcare Center 2
Los Angeles, California, 90033-5310, United States
-
Kentucky Neuroscience Institute
Lexington, Kentucky, 40536-0001, United States
-
Mount Sinai School of Medicine
New York, New York, 10029-6501, United States
-
Movement Disorder Clinic of Oklahoma PLLC
Tulsa, Oklahoma, 74136-7027, United States
-
Neurology One
Orlando, Florida, 32825, United States
-
North County Neurology Associates
Oceanside, California, 92056-4454, United States
-
Parkinson's Research Centers of America
Palo Alto, California, 94301, United States
-
Quest Research Institute - Alcanza - PPDS
Farmington Hills, Michigan, 48334-2973, United States
-
Rocky Mountain Clinical Research - CenExel - PPDS
Englewood, Colorado, 80113-2776, United States
-
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43202-4500, United States
-
The University of Kansas (KU)
Kansas City, Kansas, 66103-2078, United States
-
USF Parkinson's Disease and Movement Disorders Center
Tampa, Florida, 33613-4808, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205-5551, United States
-
University of Miami
Miami, Florida, 33136-1051, United States
-
University of Michigan Health System (UMHS)
Ann Arbor, Michigan, 48109, United States
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131-0001, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.